Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYtech Pharma has been awarded ISO 9001:2008 Certification
Lyon (France), Philadelphia (USA), November 24 2009. ERYtech Pharma has been awarded ISO9001:2008 Certification. The International Organization for Standardization is the world’s leading International Standards developer. ISO 9001:2008 specifies the requirements which have been fulfilled by
View HTML
Toggle Summary ERYTECH Pharma and Genzyme Corporation sign collaborative research agreement in rare diseases
Lyon (France) – October 12th, 2010 ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.
View HTML
Toggle Summary ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer
LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- The first clinical trial using Graspa® on a solid tumor. A good safety profile for Graspa® in last-line therapy patients. A major step forward in its flagship product deployment in solid tumors. ERYTECH Pharma has just completed the enrollment of
View HTML
Toggle Summary ERYTECH Pharma receives € 7 million from OSEO to lead the TEDAC personalized medicine project in cancer
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Jun 26, 2020 at 2:00 PM CEST

Annual General Meeting

Summary Toggle Sep 21, 2020

Business Update and Financial Highlights for the 2nd Quarter of 2020 (after U.S. market close)

Summary Toggle Sep 22, 2020 at 8:30 AM EDT

Erytech Pharma 2nd Quarter of 2020 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top